Malignant hyperthermia
Drug safety update
December 2014: Intravenous dantrolene: risk of undissolved crystals
Important safety information
Dantrolene should only be administered by, or under the direct supervision of, personnel experienced in the use of dantrolene when used for malignant hyperthermia
Dantrolene is used in the treatment of malignant hyperthermia. It acts on skeletal muscle cells by interfering with calcium efflux, thereby stopping the contractile process and reducing muscle rigidity.
| Pack | Price |
|---|---|
| 12 vial | £612.00 |
| 36 vial (3 x 12 vials) | £1,836.00 |